California has produced the kind of clinical data prevention advocates have long asked for. Teen cannabis use disorder does not sit still once a state opens the retail floodgates. A study published in the journal Addiction has the diagnosis numbers to prove it. It looks at actual clinical cases, not just survey guesses about who has tried the drug.

A Trend That Reversed Overnight

Researchers at the Public Health Institute and Kaiser Permanente Northern California went through six years of electronic health records. The data covered 637,461 adolescents. The direction they found had been improving, until it was not. In the three years before California legalised recreational cannabis in 2016, new teen cannabis use disorder diagnoses fell by roughly 6 percent a year. After the vote passed, that decline flipped into an 8 percent annual rise.

A Shift That Began Before The Shops Opened

Timing is the part worth sitting with. The upward shift in youth marijuana use disorder diagnoses started right when legalisation passed, well before a single retail shop opened its doors. The study’s authors think something beyond product availability was already at work.

Reduced criminal penalties for youth cannabis offences may have changed how teenagers weighed the consequences of use. The ballot campaign itself, with its heavy promotion, may also have signalled that cannabis carried little risk. By the time retail sales began, a cultural shift was already under way. It kept building as shops opened, product variety expanded and THC potency climbed.

The Numbers Behind The Headline

Among the adolescents studied, 8,804 received a new teen cannabis use disorder diagnosis over the six year period. By early 2020, more than three years after the law passed, diagnosis rates had climbed back to where they stood in 2014. Years of prior progress were gone.

A companion study of self reported teen cannabis use told much the same story. Use had been falling before legalisation. It began climbing once the law passed, then kept rising to a peak of 9.5 percent in early 2020. By 2024, reported use sat at 6.5 percent, close to where it stood just before the law changed. The disorder data suggests the underlying risk had shifted anyway.

Adults Show The Same Pattern

The adolescent findings sit alongside a separate national study published in JAMA Psychiatry. It analysed data from 186,823 adults between 2021 and 2024. Among men, past year cannabis use disorder prevalence rose from 7.3 to 9.3 percent. That tracked a rise in overall use from 22.2 to 25.7 percent. Among women, the disorder rate rose from 4.5 to 5.6 percent alongside similarly climbing use.

Narrow the lens to people who actually use cannabis and the numbers get harder to shrug off. In 2024, 36.2 percent of male users and 26.6 percent of female users met the criteria for cannabis use disorder. Among adults aged 18 to 20, as many as half of those who used cannabis met the criteria for the disorder. Up to 61 percent of those cases were moderate to severe.

Why Tracking Teen Cannabis Use Disorder Matters

Lead researcher Alisa Padon put the core problem plainly. Most surveys tell us how many teens have tried cannabis, not how many are developing a disorder serious enough to need clinical care. That gap matters. National survey figures on teen use have stayed roughly flat for two decades, a statistic often used as proof that legalisation has not harmed young people.

Senior author Kelly Young Wolff said that as cannabis potency has risen, families need to understand this is a product that can be addictive. For some teenagers, it requires real medical treatment. Youth marijuana use disorder carries its own risks too, including a heightened chance of suicidality and violent behaviour, particularly among young men, according to the adult study.

Treatment access has not kept pace with rising rates of moderate to severe cases. Legislation keeps expanding while public perception of the drug’s risks keeps softening. The researchers say routine screening, earlier detection and easier access to evidence based treatment would help. They also want to see pushback against the idea that cannabis carries little risk.

The California findings have limits. The study population was drawn only from insured adolescents receiving care in Northern California. Results may not translate to other regions or to uninsured teens. Because the law applied statewide, researchers had no unexposed comparison group. The analysis also ended before the COVID 19 pandemic began, which limits what can be said about longer term trends. Even so, the California diagnosis data lines up with the separate national adult study closely enough that coincidence is a hard sell.

Source: dbrecoveryresources